急性水様性下痢の単回投与抗生物質治療、リファキシミン対アジスロマイシン、ロペラミド補助剤付き (TrEAT_TD2)
急性水様性下痢の治療のための単回投与リファキシミンとロペラミド補助剤を併用したアジスロマイシンを評価するランダム化比較試験
The purpose of this study is to compare a single dose of rifaximin with loperamide to the current standard approach of single dose azithromycin with loperamide for the treatment of acute watery traveler's diarrhea (TD).
The study requires 1) taking a single dose antibiotic plus loperamide to treat TD, 2) providing blood and stool samples at different time points to evaluate infection and immune responses, 3) completing a daily symptom diary following treatment, 4) being seen by the study doctor to monitor illness and recovery, and 5) completing a brief electronic questionnaire at 3 months.
Participants will be randomly assigned to one of the two treatment groups. The two groups are 1) rifaximin 550 mg as a single dose with loperamide or 2) azithromycin 500 mg as a single dose with loperamide. Both groups will take the antibiotic dose with 4 mg of loperamide. Participants are provided additional loperamide with instructions that they may take a 2 mg after continued diarrheal stools up to a maximum of 8 mg per day as needed.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 4
連絡先と場所
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Active duty military, 18-60 years old
- Presence of acute watery diarrhea (3 or more loose/liquid stools in 24 hours or 2 loose/liquid stools in 24 hours and associated symptoms such as nausea, vomiting, abdominal cramps or tenesmus) lasting <96 hours in duration that impacts function in activities and/or performance of primary duties. Refer to recruitment decision tree below.
- Eligible for ambulatory management. (Note: Ambulatory management in this study means that the patient can be treated on an outpatient basis to include up to 23 hours of medical observation and IV therapies.)
- Able to comply with follow-up procedures.
- Will remain in country for at least 7 days or an assurance that follow-up can be arranged elsewhere.
Exclusion Criteria:
- Allergy to rifamycins, macrolides, or loperamide (not including mild gastrointestinal upset).
- Antibiotic therapy in the 72 hours prior to presentation (excluding malaria prophylaxis with mefloquine, malarone, chloroquine/proguanil, tafenoquine, or doxycycline).
- Concomitant medications with known drug-drug interactions with any of the study drugs (includes theophylline, digoxin, warfarin, chloroquine and hydroxychloroquine).
- Current or history of liver disease or other serious health conditions based on review by study physician.
- Acute dysentery and/or febrile illness (temperature > 100.4°F [38.1°C]).
- Presence of symptoms >96 hours prior to initiating treatment.
- Use of >4 mg loperamide or use of any amount of loperamide for greater than 24 hours prior to enrollment. Prior use of bismuth subsalicylate or other anti-diarrheal, non-antibiotic therapy in the 48 hours prior to enrollment.
- Positive pregnancy test at presentation (unknown effects with rifaximin). All female participants will be administered a urine pregnancy test prior to enrollment.
- Previously screened or randomized in this study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:ロペラミドとリファキシミン
|
Rifaximin 550 mg as a single dose administered orally. 4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool). |
|
アクティブコンパレータ:ロペラミドを含むアジスロマイシン mg
|
4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool). Azithromycin 500 mg as a single dose administered orally. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Therapeutic Efficacy: Time to Last Unformed Stool (TLUS)
時間枠:Up to 1 week (up to 168 hours)
|
The primary efficacy endpoint is the time to last unformed stool (TLUS). TLUS is calculated from the time of antibiotic dose to last unformed stool meeting the pre-defined traveler's diarrhea definition. |
Up to 1 week (up to 168 hours)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Clinical Cure Rate
時間枠:24, 48, and 72 hours
|
The clinical efficacy cure rate is the percentage of participants that met criteria for both diarrhea resolution and symptom resolution within the specified window, at 24, 48, and 72 hours following initial study treatment. To meet criteria for symptom resolution, there must be no traveler's diarrhea (TD) associated symptoms reported as moderate or greater and no impact on activities for last 24 hour period. |
24, 48, and 72 hours
|
|
Return to Normal Activities
時間枠:24, 48, and 72 hours
|
The percentage of participants that reported activities were not impacted at the end of the specified window, at 24, 48, and 72 hours following initial study treatment. |
24, 48, and 72 hours
|
|
Number of Participants With Recurrence of Traveler's Diarrhea
時間枠:7 days
|
Participants that experienced a recurrence of traveler's diarrhea after previously meeting criteria for clinical cure resolution. |
7 days
|
|
Number of Participants Requiring Rescue Treatment
時間枠:3 days
|
The number of participants whose illness worsened or continued to impact functional capacity at the 72-hour time point requiring their treatment code to be broken so appropriate rescue treatment could be prescribed. |
3 days
|
協力者と研究者
スポンサー
スポンサー
協力者
協力者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- IDCRP-115
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。